Navigation Links
Masimo Reports Second Quarter 2012 Financial Results
Date:8/1/2012

ce market growth.  Our end-user, or direct, business delivered even stronger growth at 16% versus the second quarter of 2011, fueled by increased consumable sales in the U.S., Europe, Asia and other regions. This performance is a testament to the superiority of our gold standard Masimo SET pulse oximetry technology and the growing appeal of our breakthrough Masimo rainbow SET platform, which is the first and only platform to provide continuous, noninvasive monitoring of carbon monoxide, total hemoglobin, methemoglobin, fluid responsiveness and respiration rate."

As of June 30, 2012, cash and cash equivalents were $121.5 million, compared to $129.9 million as of December 31, 2011.  The change reflects primarily net cash generated from operations, offset by $7.2 million in cash used to purchase the assets of Spire Semiconductor in March 2012 and $26.3 million in cash used to repurchase shares of Masimo common stock.  In the second quarter of 2012, the company completed its full three million share repurchase program authorized by the Board of Directors in August 2011. 

Financial Guidance
Masimo today announced the acquisition of PHASEIN, AB and, as a result, is providing updated 2012 financial guidance.  Masimo now expects total revenue of approximately $494 million, including $466 million in product revenue and $28 million in royalty revenue.  This compares to prior guidance of $458 million in product revenue and $28 million in royalty revenue.  As a result of the acquisition, Masimo estimates a $0.04 dilutive impact on its previous 2012 EPS guidance of approximately $1.15.  In addition, Masimo is also updating its guidance for the remainder of 2012 to reflect slightly lower product gross profit margin expectations, a slightly higher effective tax rate and the inclusion of first half 2012 foreign exchange losses.  The impact of these revisions to guidance is offset by the $0.03 tax benefit the company rec
'/>"/>

SOURCE Masimo Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Masimo Signs Pulse Oximetry Distribution Deal with MWI Veterinary Supply
2. Masimo to Report Second Quarter 2012 Financial Results after Market Close on August 1
3. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
4. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
5. Masimo CEO Joe Kiani Named Ernst & Young Entrepreneur of the Year
6. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
7. Novation Inks Supplier Contract Category Agreement for Masimo SET® pulse oximetry and rainbow® SET Pulse CO-Oximetry™
8. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Hanger, Inc. Reports Earnings of $0.50 Per Diluted Share for the Second Quarter 2012
11. Onyx Pharmaceuticals Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 27, 2011 Water Street Healthcare Partners , ... care, announced today that it has acquired MarketLab, ... firm,s fourth in the specialty healthcare distribution sector.  The ... companies specializing in distribution, life sciences, medical devices and ...
... 2011 Pacira Pharmaceuticals, Inc ., (Nasdaq: ... announced that it has been included in the Russell ... set of U.S. and global equity indexes on June ... measures the performance of the 3,000 largest U.S. companies ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. ... General Hospital Emergency Room – Gilbert, opening in August. The new facility is ... in the West Valley. , “Dr. Baldwin is an excellent leader and will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
(Date:8/2/2015)... ... 03, 2015 , ... A new Phase I research study is looking at ... led by Kenneth G. Lucas, M.D. , chief of the division of pediatric ... at Kosair Children’s Hospital and in the UofL Department of Pediatrics ...
(Date:8/1/2015)... ... ... Back packs can be dangerous? Whaaat?! , Not the danger that guns ... a kid's spine. With school starting again, most kids will be asking for new ... aware of how to help them prevent injuries by understanding backpack safety. , "Carrying ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2
... is an essential element of care for children requiring ... combining ketamine and propofol, two common medications used in ... it was unclear whether this practice was superior to ... Research led by Drs. Amit Shah, Gregory Mosdossy ...
... prostate cancer should be especially diligent about having routine ... at the University at Buffalo indicate. , Their findings ... more abnormal colon polyps, known as adenomas, and advanced ... of the research were presented Oct. 19 at a ...
... October 18, 2010 Neuralstem, Inc. (NYSE Amex: ... human clinical trial of the company,s spinal cord stem ... or Lou Gehrig,s disease) at Emory University in Atlanta, ... data from the first six non-ambulatory patients, the trial,s ...
... HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... victim to stunning medical mistakes, ranging from an operation ... for another patient, a new study finds. To ... Joint Commission in 2004 introduced a universal protocol for ...
... Mozes HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... may raise the risk for heart attack and stroke, researchers ... short-term, the study team noted. "I don,t want to ... cardiovascular risk in the period just after dental work was ...
... likely to buy unhealthy foods when they pay using ... in the Journal of Consumer Research . ... authors Manoj Thomas (Cornell University), Kalpesh Kaushik Desai (State ... University of New York, Buffalo). "First, there is a ...
Cached Medicine News:Health News:Study reveals superior sedation method for children 2Health News:Prostate cancer patients are at increased risk of precancerous colon polyps 2Health News:Neuralstem updates ALS clinical trial progress 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 3Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 4Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 2Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 3Health News:Cash is healthier? Credit and debit increase impulsive food purchases 2
... Isolation Kit (patent pending) is designed for ... / or Newcastle Disease (ND) viral RNA ... samples. This kit id validated by the ... their testing protocol for real-time RT-PCR detection ...
... This revolutionary product will provide ... any type of electroretinogram, visual evoked ... LED ganzfeld will allow you to ... including on-off, double flash, photopic negative ...
... LABOTECH is an automated microplate ... immunoenzymatic microplate techniques. Open architecture ... to many manufacturers' microplate assays ... traditional R.I.A. and I.F.A. methods ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: